We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$694M
1-Year Est. Return
79.73%
This Fund
S&P 500
This Quarter
Est. Return
+15.35%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$328M
AUM Growth
+$67.2M
(+26%)
Cap. Flow
+$47.5M
Cap. Flow
% of AUM
14.5%
Top 10 Holdings %
Top 10 Hldgs %
41.01%
Holding
89
New
15
Increased
27
Reduced
12
Closed
21
Top Buys
| 1 |
Biogen
BIIB
|
+$24.7M |
| 2 |
CVS Health
CVS
|
+$13.7M |
| 3 |
GSK
GSK
|
+$10.5M |
| 4 |
Gilead Sciences
GILD
|
+$9.94M |
| 5 |
Globus Medical
GMED
|
+$9.18M |
Top Sells
| 1 |
Cencora
COR
|
+$9.96M |
| 2 |
Cigna
CI
|
+$9.92M |
| 3 |
Cardinal Health
CAH
|
+$9.32M |
| 4 |
CELG
Celgene Corp
CELG
|
+$6.56M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$6.31M |
Sector Composition
| 1 | Healthcare | 91% |
| 2 | Industrials | 1.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CVS Health
CVS
$135B
| $19.8M | 6.04% |
367,071
+222,294
| +154% | +$13.7M |
|
|
2
Biogen
BIIB
$28.3B
| $18.6M | 5.67% |
+78,596
| New | +$24.7M |
|
|
3
Gilead Sciences
GILD
$161B
| $16M | 4.88% |
245,968
+149,488
| +155% | +$9.94M |
|
4
HCA Healthcare
HCA
$80.7B
| $14M | 4.27% |
107,428
+39,389
| +58% | +$5.29M |
|
5
Medtronic
MDT
$102B
| $12M | 3.65% |
131,464
+349
| +0.3% | +$31.2K |
|
|
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $11.2M | 3.43% |
766,980
+323,571
| +73% | +$3.72M |
|
|
7
GSK
GSK
$103B
| $10.9M | 3.34% |
+209,600
| New | +$10.5M |
|
8
Medpace
MEDP
$15.3B
| $10.7M | 3.27% |
181,866
+118,686
| +188% | +$7.09M |
|
9
Ascendis Pharma A/S
ASND
$17.4B
| $10.6M | 3.24% |
+90,325
| New | +$7.91M |
|
|
GWPH
10
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $10.5M | 3.2% |
62,186
-22,000
| -26% | -$3.27M |
|
|
11
Globus Medical
GMED
$10.3B
| $10M | 3.06% |
+202,827
| New | +$9.18M |
|
12
Emergent Biosolutions
EBS
$387M
| $9.1M | 2.78% |
180,156
+106,363
| +144% | +$6.27M |
|
|
NVO
13
Novo Nordisk
NVO
$217B
| $8.47M | 2.59% |
324,000
+29,244
| +10% | +$719K |
|
14
Viking Therapeutics
VKTX
$4.41B
| $8.47M | 2.58% |
852,160
+215,114
| +34% | +$1.8M |
|
|
15
Alnylam Pharmaceuticals
ALNY
$37.6B
| $7.4M | 2.26% |
79,153
-75,484
| -49% | -$6.31M |
|
|
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.36M | 2.25% |
530,175
+360,918
| +213% | +$4.13M |
|
|
LITS
17
Lite Strategy Inc
LITS
$33.9M
| $7.24M | 2.21% |
117,832
-860
| -0.7% | -$49.3K |
|
18
Sanofi
SNY
$103B
| $6.95M | 2.12% |
156,854
-111,534
| -42% | -$4.78M |
|
19
Molina Healthcare
MOH
$12.6B
| $6.38M | 1.95% |
44,928
+2,059
| +5% | +$278K |
|
20
McKesson
MCK
$94.1B
| $6M | 1.83% |
51,300
+4,770
| +10% | +$589K |
|
|
SPPI
21
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $5.92M | 1.81% |
+554,019
| New | +$5.93M |
|
|
WCG
22
DELISTED
Wellcare Health Plans, Inc.
WCG
| $5.79M | 1.77% |
+21,459
| New | +$5.54M |
|
23
Vertex Pharmaceuticals
VRTX
$121B
| $5.19M | 1.58% |
+28,232
| New | +$5.21M |
|
|
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.86M | 1.48% |
1,295,669
+144,159
| +13% | +$540K |
|
|
ALXN
25
DELISTED
Alexion Pharmaceuticals
ALXN
| $4.79M | 1.46% |
35,421
+18,421
| +108% | +$2.29M |
|
Similar funds
IIC
MCM
CGIC
HA
BBPWM
M
HG
CA